MedTrace Logo

To Evaluate the Clinical Efficacy of Probiotics in Patients With the Breast Cancer

NCT06039644 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-03-06

No results posted yet for this study

Summary

Chemotherapy-associated side-effects would affect therapeutic effect, quality of life, and cause permanent harm to breast cancer patients. This study is designed to explore after consumption of probiotics of lactobacillus composite strain powder sachets for 6 months in breast cancer chemotherapy, and whether the improvement of meliorate the side effects, further assists patients completing the chemotherapy.

Conditions

Interventions

DIETARY_SUPPLEMENT

Probiotic

Three-strain probiotic supplement includes Lactobacillus reuteri GMNL-89 (alive), Lactobacillus plantarum GMNL-141 (alive) and Lactobacillus paracasei GMNL-133 (alive).

OTHER

Placebo

Same additives to Probiotic group but replace probiotics with corn starch and Maltodextrin.

Sponsors & Collaborators

  • Mackay Memorial Hospital

    collaborator OTHER

  • GenMont Biotech Incorporation

    lead INDUSTRY

Principal Investigators

  • Po-Sheng Yang, MD, PhD · Mackay Memorial Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-08
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06039644 on ClinicalTrials.gov